KROS vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 15, 2026

KROS

49.7
AI Score
VS
KROS Wins

CBIO

38.0
AI Score

Investment Advisor Scores

KROS

50score
Recommendation
HOLD

CBIO

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric KROS CBIO Winner
Revenue 32,000 1.04M CBIO
Net Income -52.42M -48.12M CBIO
Net Margin -163806.3% -4631.4% CBIO
Operating Income -56.81M -51.09M CBIO
ROE -20.0% -29.5% KROS
ROA -18.2% -26.3% KROS
Total Assets 287.60M 182.76M KROS
Cash 257.61M 171.59M KROS
Current Ratio 21.96 9.66 KROS
Free Cash Flow -24.18M -28.56M KROS

Relative Price Performance (Last 90 Days)

KROS 1M: +8.8% · 3M: -1.7% CBIO 1M: +0.7% · 3M: -15.2%

Current Technical Phase

KROS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 55

RSI (14): 55.0 · Price: $11.03

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 53.0 · Price: $17.15

Fundamentals Snapshot

Metric KROS CBIO
Market Cap
Forward P/E -1.7 -6.5
Trailing P/E
Revenue (TTM)
Revenue Growth -1.0% 0.0%
Gross Margin -3.9% 1.0%
Operating Margin -6.6% -14.3%
EPS -3.18 -0.13
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, KROS is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.